Journal of clinical virology plus最新文献_第2页

What is the proportion of samples reported as positive among reactive samples in Siemens Atellica IM analyzer HIV and HCV serological screening? 在Siemens Atellica IM分析仪的HIV和HCV血清学筛查中，阳性样本的比例是多少？

IF 1.4 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-11-01 Epub Date: 2025-10-10 DOI: 10.1016/j.jcvp.2025.100232

Jesper M. Kivelä, Anne Toivonen, Maarit Ahava, Satu Kurkela

Background

Serological screening of transmissible blood-borne viruses, like HIV and HCV, is a seminal part of medical laboratory workflow. Reliable screening methods are vital to provide impetus for confirmation testing, since false reactive results occur with HIV and HCV immunoassays.

Objectives

We analyzed what proportion of the reactive HIV Ag/Ab and anti-HCV serum samples with Siemens Atellica IM Analyzer were finally reported as positive after confirmation testing.

Study design

Reactive samples with Atellica IM Analyzers using HIV Ag/Ab Combo Assay (HIV Ag/Ab) or Atellica IM Hepatitis C assay (anti-HCV) analyzed between 1/2021-4/2023 were queried from our laboratory system. Index cut-off for reactive sample was ≥1.00 for HIV Ag/Ab and ≥0.80 for anti-HCV. All reactive samples underwent confirmation testing and were interpreted by clinical microbiologists. We calculated the proportion of positive results amidst reactive samples with Atellica IM Analyzers. We used index categorization based on our laboratory workflow for confirmation testing.

Results

Of 802 reactive HIV Ag/Ab and 3100 reactive anti-HCV samples, 69 % (95 % CI 66-72 %) and 96 % (95 % CI 95-97 %) were eventually reported positive. Reactive samples with an index over measurement range were almost exclusively reported as positive with high posterior probabilities. Reactive HIV Ag/Ab samples within a very low or low reactivity category were seldom reported as positive.

Conclusions

Most reactive samples with Atellica IM Analyzer were reported positive, nonetheless up to 31 % of HIV Ag/Ab and 4 % of anti-HCV samples were false reactives. These data can be utilized in designing algorithms for confirmation testing in clinical laboratories.

背景：血液传播病毒（如HIV和HCV）的血清学筛查是医学实验室工作流程的重要组成部分。可靠的筛查方法对于提供确认检测的动力至关重要，因为HIV和HCV免疫测定会出现假反应结果。目的分析西门子Atellica IM分析仪检测的HIV Ag/Ab阳性和抗hcv阳性血清样本经确证后最终报告阳性的比例。研究设计从我们的实验室系统中查询在2021年1月至2023年4月期间使用Atellica IM分析仪使用HIV Ag/Ab组合检测（HIV Ag/Ab）或Atellica IM丙型肝炎检测（anti-HCV）分析的反应性样品。阳性样本HIV Ag/Ab指数临界值≥1.00，抗hcv指数临界值≥0.80。所有反应性样品都经过了确认测试，并由临床微生物学家进行了解释。我们用Atellica IM分析仪计算了反应样品中阳性结果的比例。我们使用索引分类基于我们的实验室工作流程进行确认测试。结果802份HIV Ag/Ab阳性样本和3100份抗hcv阳性样本中，分别有69% （95% CI 66 ~ 72%）和96% （95% CI 95 ~ 97%）最终呈阳性。指数超过测量范围的反应性样品几乎完全报告为具有高后验概率的阳性。极低或低反应性类别的反应性HIV Ag/Ab样本很少报告为阳性。结论大多数用Atellica IM分析仪检测的样本呈阳性，但高达31%的HIV Ag/Ab和4%的抗- hcv样本呈假反应。这些数据可用于设计临床实验室确认测试的算法。

{"title":"What is the proportion of samples reported as positive among reactive samples in Siemens Atellica IM analyzer HIV and HCV serological screening?","authors":"Jesper M. Kivelä, Anne Toivonen, Maarit Ahava, Satu Kurkela","doi":"10.1016/j.jcvp.2025.100232","DOIUrl":"10.1016/j.jcvp.2025.100232","url":null,"abstract":"<div><h3>Background</h3><div>Serological screening of transmissible blood-borne viruses, like HIV and HCV, is a seminal part of medical laboratory workflow. Reliable screening methods are vital to provide impetus for confirmation testing, since false reactive results occur with HIV and HCV immunoassays.</div></div><div><h3>Objectives</h3><div>We analyzed what proportion of the reactive HIV Ag/Ab and anti-HCV serum samples with Siemens Atellica IM Analyzer were finally reported as positive after confirmation testing.</div></div><div><h3>Study design</h3><div>Reactive samples with Atellica IM Analyzers using HIV Ag/Ab Combo Assay (HIV Ag/Ab) or Atellica IM Hepatitis C assay (anti-HCV) analyzed between 1/2021-4/2023 were queried from our laboratory system. Index cut-off for reactive sample was ≥1.00 for HIV Ag/Ab and ≥0.80 for anti-HCV. All reactive samples underwent confirmation testing and were interpreted by clinical microbiologists. We calculated the proportion of positive results amidst reactive samples with Atellica IM Analyzers. We used index categorization based on our laboratory workflow for confirmation testing.</div></div><div><h3>Results</h3><div>Of 802 reactive HIV Ag/Ab and 3100 reactive anti-HCV samples, 69 % (95 % CI 66-72 %) and 96 % (95 % CI 95-97 %) were eventually reported positive. Reactive samples with an index over measurement range were almost exclusively reported as positive with high posterior probabilities. Reactive HIV Ag/Ab samples within a very low or low reactivity category were seldom reported as positive.</div></div><div><h3>Conclusions</h3><div>Most reactive samples with Atellica IM Analyzer were reported positive, nonetheless up to 31 % of HIV Ag/Ab and 4 % of anti-HCV samples were false reactives. These data can be utilized in designing algorithms for confirmation testing in clinical laboratories.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100232"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145415708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of dried blood spot vs. venous sample collection on SARS-CoV-2 antibody test results in the CLSA serological study of older Canadians 在加拿大老年人里昂证券血清学研究中，干血斑与静脉标本采集对SARS-CoV-2抗体检测结果的影响

IF 1.4 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-11-01 Epub Date: 2025-11-25 DOI: 10.1016/j.jcvp.2025.100236

Jiacheng Chen , Yuan Yu , Steven J. Drews , W. Alton Russell

Background

Participant-collected dried blood spots (DBS), which can be returned using regular mail, are convenient for collecting samples for population serology studies. The impact of DBS sampling on assay performance remains unclear.

Objective

We estimated the impact of using DBS samples on estimates of population SARS-CoV-2 antibody levels within a study of older Canadians.

Study Design

Analyzing data from 3 796 participants who provided DBS samples and 3 457 participants who provided venous samples, we estimated the impact of sample collection modality on odds of testing positive for anti-nucleocapsid antibodies (Anti-N) or for antibodies to the SARS-CoV-2 spike protein (Anti-S) using the Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S immunoassays. We used inverse probability of treatment weighting to control for differences between participants who provided DBS or venous samples, including sample collection date and participants’ age, vaccination status, and geographic location.

Results

Compared to venous samples, DBS samples were less likely to be Anti-N positive (weighted risk ratio [RR]: 0.30, 95 % confidence interval [CI]: 0.25–0.36) and less likely to be Anti-S positive (RR: 0.83, 95 % CI: 0.80–0.86). We estimate that using DBS for all participants would have underestimated seropositivity for anti-N antibodies (2.48 % using DBS; 8.32 % using venous) and anti-S antibodies (42.7 % using DBS; 51.6 % using venous).

Discussion

In population serology studies, DBS samples should only be used instead of venous blood draws when the impact on assay performance is well-characterized and appropriate adjustments are used to derive population seropositivity estimates.

参与者采集的干血斑（DBS）可通过普通邮件返回，便于收集人群血清学研究的样本。DBS取样对分析性能的影响尚不清楚。目的：在一项针对加拿大老年人的研究中，我们估计了使用DBS样本对估计人群SARS-CoV-2抗体水平的影响。研究设计分析了提供DBS样本的3 796名参与者和提供静脉样本的3 457名参与者的数据，我们使用Elecsys Anti-SARS-CoV-2和Anti-SARS-CoV-2 S免疫测定，估计了样本收集方式对抗核衣壳抗体（Anti-N）或抗SARS-CoV-2刺突蛋白（Anti-S）抗体检测阳性几率的影响。我们使用治疗加权逆概率来控制提供DBS或静脉样本的参与者之间的差异，包括样本收集日期和参与者的年龄、疫苗接种状况和地理位置。结果与静脉标本相比，DBS标本抗- n阳性的可能性较低（加权风险比[RR]: 0.30, 95%可信区间[CI]: 0.25 ~ 0.36），抗- s阳性的可能性较低（RR: 0.83, 95% CI: 0.80 ~ 0.86）。我们估计，对所有参与者使用DBS会低估抗n抗体（使用DBS的比例为2.48%，使用静脉的比例为8.32%）和抗s抗体（使用DBS的比例为42.7%，使用静脉的比例为51.6%）的血清阳性。在人群血清学研究中，只有当DBS样本对检测性能的影响得到充分表征，并且使用适当的调整来得出人群血清阳性估计时，才应该使用DBS样本来代替静脉血。

{"title":"Impact of dried blood spot vs. venous sample collection on SARS-CoV-2 antibody test results in the CLSA serological study of older Canadians","authors":"Jiacheng Chen , Yuan Yu , Steven J. Drews , W. Alton Russell","doi":"10.1016/j.jcvp.2025.100236","DOIUrl":"10.1016/j.jcvp.2025.100236","url":null,"abstract":"<div><h3>Background</h3><div>Participant-collected dried blood spots (DBS), which can be returned using regular mail, are convenient for collecting samples for population serology studies. The impact of DBS sampling on assay performance remains unclear.</div></div><div><h3>Objective</h3><div>We estimated the impact of using DBS samples on estimates of population SARS-CoV-2 antibody levels within a study of older Canadians.</div></div><div><h3>Study Design</h3><div>Analyzing data from 3 796 participants who provided DBS samples and 3 457 participants who provided venous samples, we estimated the impact of sample collection modality on odds of testing positive for anti-nucleocapsid antibodies (Anti-N) or for antibodies to the SARS-CoV-2 spike protein (Anti-S) using the Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S immunoassays. We used inverse probability of treatment weighting to control for differences between participants who provided DBS or venous samples, including sample collection date and participants’ age, vaccination status, and geographic location.</div></div><div><h3>Results</h3><div>Compared to venous samples, DBS samples were less likely to be Anti-N positive (weighted risk ratio [RR]: 0.30, 95 % confidence interval [CI]: 0.25–0.36) and less likely to be Anti-S positive (RR: 0.83, 95 % CI: 0.80–0.86). We estimate that using DBS for all participants would have underestimated seropositivity for anti-N antibodies (2.48 % using DBS; 8.32 % using venous) and anti-S antibodies (42.7 % using DBS; 51.6 % using venous).</div></div><div><h3>Discussion</h3><div>In population serology studies, DBS samples should only be used instead of venous blood draws when the impact on assay performance is well-characterized and appropriate adjustments are used to derive population seropositivity estimates.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100236"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145684125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“Systematic review of HHV-6 and febrile seizures: Should the ER include it in the viral panel?” “对HHV-6和热性惊厥的系统回顾：急诊室是否应将其纳入病毒检查小组？”

IF 1.4 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-11-01 Epub Date: 2025-10-23 DOI: 10.1016/j.jcvp.2025.100233

Valerie Foy , Shaina Gagadam

Background

Human herpesvirus 6 (HHV-6), particularly subtype B, is a common viral infection in childhood and the cause of roseola infantum. Beyond its dermatologic effects, HHV-6B is an important yet often underrecognized contributor to febrile seizures in young children presenting to the emergency department (ED).

Objective

This systematic review aims to examine the virology, epidemiology, and clinical features of HHV-6 infection in children, focusing on neurologic manifestations, while evaluating current ED diagnostic practices and the potential role for HHV-6 testing in pediatric febrile seizures.

Methods

Following PRISMA guidelines, a comprehensive search of PubMed and Embase databases identified studies published up to September 2025 on HHV-6 virology, dermatologic findings, neurologic complications, and ED management in pediatric patients. Inclusion criteria focused on HHV-6′s role in febrile seizures and the utility of rapid molecular diagnostics in the ED. Search terms included keywords related to HHV-6, febrile seizures, and pediatric emergency care. Two reviewers independently performed full-text reviews and extracted data.

Results

Primary HHV-6B infection affects most children by age two, with up to 30 % of first febrile seizures in this group attributed to the virus. While mostly self-limited, HHV-6B is disproportionately associated with complex febrile seizures and febrile status epilepticus. Emerging rapid diagnostic tools offer opportunities for targeted testing in select high-risk populations but are costly.

Conclusions

HHV-6B is an underrecognized cause of febrile seizures in pediatrics. Selective screening for complex or prolonged seizures may enhance improve long-term outcomes. Until stronger evidence emerges, clinicians should interpret HHV-6B results within the broader clinical context.

人类疱疹病毒6 (HHV-6)，特别是B亚型，是儿童时期常见的病毒感染，也是婴儿红疹的病因。除了它的皮肤效应，HHV-6B是一个重要的，但往往被低估的贡献者热性癫痫发作的幼儿呈现到急诊科（ED）。目的本系统综述旨在探讨儿童HHV-6感染的病毒学、流行病学和临床特征，重点关注神经学表现，同时评估当前ED的诊断方法和HHV-6检测在儿童热性惊厥中的潜在作用。方法：根据PRISMA指南，对PubMed和Embase数据库进行全面检索，确定截至2025年9月发表的关于HHV-6病毒学、皮肤病学发现、神经系统并发症和儿科患者ED管理的研究。纳入标准侧重于HHV-6在热性惊厥中的作用以及快速分子诊断在急诊科中的应用。搜索词包括与HHV-6、热性惊厥和儿科急诊相关的关键词。两名审稿人独立进行全文审查并提取数据。结果HHV-6B原发感染影响大多数2岁儿童，该组中高达30% %的首次发热性惊厥归因于该病毒。虽然大多数是自限性的，但HHV-6B与复杂的热性惊厥和热性癫痫持续状态不成比例地相关。新兴的快速诊断工具为选定的高危人群提供了有针对性的检测机会，但费用昂贵。结论shhv - 6b是一种未被充分认识的儿科热性惊厥病因。对复杂或长时间癫痫发作进行选择性筛查可提高长期预后。在更有力的证据出现之前，临床医生应该在更广泛的临床背景下解释HHV-6B的结果。

{"title":"“Systematic review of HHV-6 and febrile seizures: Should the ER include it in the viral panel?”","authors":"Valerie Foy , Shaina Gagadam","doi":"10.1016/j.jcvp.2025.100233","DOIUrl":"10.1016/j.jcvp.2025.100233","url":null,"abstract":"<div><h3>Background</h3><div>Human herpesvirus 6 (HHV-6), particularly subtype B, is a common viral infection in childhood and the cause of roseola infantum. Beyond its dermatologic effects, HHV-6B is an important yet often underrecognized contributor to febrile seizures in young children presenting to the emergency department (ED).</div></div><div><h3>Objective</h3><div>This systematic review aims to examine the virology, epidemiology, and clinical features of HHV-6 infection in children, focusing on neurologic manifestations, while evaluating current ED diagnostic practices and the potential role for HHV-6 testing in pediatric febrile seizures.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines, a comprehensive search of PubMed and Embase databases identified studies published up to September 2025 on HHV-6 virology, dermatologic findings, neurologic complications, and ED management in pediatric patients. Inclusion criteria focused on HHV-6′s role in febrile seizures and the utility of rapid molecular diagnostics in the ED. Search terms included keywords related to HHV-6, febrile seizures, and pediatric emergency care. Two reviewers independently performed full-text reviews and extracted data.</div></div><div><h3>Results</h3><div>Primary HHV-6B infection affects most children by age two, with up to 30 % of first febrile seizures in this group attributed to the virus. While mostly self-limited, HHV-6B is disproportionately associated with complex febrile seizures and febrile status epilepticus. Emerging rapid diagnostic tools offer opportunities for targeted testing in select high-risk populations but are costly.</div></div><div><h3>Conclusions</h3><div>HHV-6B is an underrecognized cause of febrile seizures in pediatrics. Selective screening for complex or prolonged seizures may enhance improve long-term outcomes. Until stronger evidence emerges, clinicians should interpret HHV-6B results within the broader clinical context.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100233"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145519939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of inflammatory markers including neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, platelet distribution width, and red blood cell distribution width in viral hepatitis: A systematic review and meta-analysis 中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、平均血小板体积、血小板分布宽度和红细胞分布宽度在病毒性肝炎中的预后价值：一项系统综述和荟萃分析

IF 1.4 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-11-01 Epub Date: 2025-08-12 DOI: 10.1016/j.jcvp.2025.100229

Peyvand Parhizkar Roudsari , Shayan Shojaei , Parisa Firoozbakhsh , Alireza Azarboo , Saeed Mirmoosavi , Ali Moradi , Faeze Abbaspour , Asma Mousavi , Hanieh Radkhah

Background

Hematological markers offer valuable and cost-effective tools for hepatitis prognosis and treatment customization due to their role in inflammatory responses. Hence, this study seeks to explore the prognostic potential of inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) in viral hepatitis patients.

Methods

We conducted a systematic search in online databases of PubMed, Web of Science, Scopus, and Cochrane for related articles following PRISMA guidelines. Our endpoint was to evaluate the association between NLR, PLR, MPV, PDW, and RDW with fibrosis and cirrhosis outcomes in patients with hepatitis B and C. The analysis used the "meta" package in R, employing Hedges' g to calculate the standardized mean difference (SMD) and 95 % confidence intervals (CI). A P value less than 0.05 was considered statistically significant for all data analyses

Results

Thirty-seven studies were ultimately included in the analysis. PLR was higher in mild fibrosis (SMD = -0.48, 95 % CI: -0.90; -0.06), with no significant differences observed by hepatitis type. Both MPV and RDW were higher in advanced fibrosis (MPV: SMD = 0.36, 95 % CI: 0.19; 0.53, RDW: SMD = 0.32, 95 % CI: 0.14; 0.50), and they were significantly increased in advanced hepatitis C fibrosis. PDW was higher in advanced fibrosis (SMD = 0.32, 95 % CI: 0.02; 0.61), significantly in hepatitis B. In cirrhotic versus non-cirrhotic patients, MPV (SMD = 0.22, 95 % CI: 0.07; 0.38) and RDW (SMD = 1.35, 95 % CI: 0.62; 2.08) were higher in the cirrhotic group, while PLR (SMD = -1.15, 95 % CI: -2.16; -0.15) was higher in the non-cirrhotic group. NLR showed no significant difference between mild and advanced fibrosis or between cirrhotic and non-cirrhotic groups.

Conclusion

This meta-analysis reveals the importance of hematological parameters of MPV, PDW, RDW, and PLR as predictors of viral hepatitis progression. MPV, PDW, and RDW are elevated in advanced fibrosis, while PLR is notably higher in mild fibrosis.

血液学标志物由于其在炎症反应中的作用，为肝炎预后和治疗定制提供了有价值且具有成本效益的工具。因此，本研究旨在探讨炎症标志物在病毒性肝炎患者中的预后潜力，包括中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、平均血小板体积（MPV）、血小板分布宽度（PDW）和红细胞分布宽度（RDW）。方法系统检索PubMed、Web of Science、Scopus、Cochrane等在线数据库，根据PRISMA指南检索相关文章。我们的终点是评估NLR、PLR、MPV、PDW和RDW与乙型肝炎和丙型肝炎患者纤维化和肝硬化结局之间的关系。分析使用R中的“meta”包，使用Hedges' g计算标准化平均差（SMD）和95%置信区间（CI）。P值小于0.05认为所有数据分析均有统计学意义。结果37项研究最终纳入分析。轻度纤维化的PLR较高（SMD = -0.48, 95% CI: -0.90; -0.06），不同肝炎类型间无显著差异。MPV和RDW在晚期丙型肝炎纤维化中均较高（MPV: SMD = 0.36, 95% CI: 0.19; 0.53, RDW: SMD = 0.32, 95% CI: 0.14; 0.50），在晚期丙型肝炎纤维化中MPV和RDW均显著升高。在肝硬化和非肝硬化患者中，肝硬化组的MPV （SMD = 0.22, 95% CI: 0.07; 0.38）和RDW （SMD = 1.35, 95% CI: 0.62; 2.08）更高，而非肝硬化组的PLR （SMD = -1.15, 95% CI: -2.16; -0.15）更高。轻度和晚期纤维化、肝硬化组和非肝硬化组之间NLR无显著差异。结论：本荟萃分析揭示了血液学参数MPV、PDW、RDW和PLR作为病毒性肝炎进展预测因子的重要性。MPV、PDW和RDW在晚期纤维化中升高，而PLR在轻度纤维化中显著升高。

{"title":"Prognostic value of inflammatory markers including neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, platelet distribution width, and red blood cell distribution width in viral hepatitis: A systematic review and meta-analysis","authors":"Peyvand Parhizkar Roudsari , Shayan Shojaei , Parisa Firoozbakhsh , Alireza Azarboo , Saeed Mirmoosavi , Ali Moradi , Faeze Abbaspour , Asma Mousavi , Hanieh Radkhah","doi":"10.1016/j.jcvp.2025.100229","DOIUrl":"10.1016/j.jcvp.2025.100229","url":null,"abstract":"<div><h3>Background</h3><div>Hematological markers offer valuable and cost-effective tools for hepatitis prognosis and treatment customization due to their role in inflammatory responses. Hence, this study seeks to explore the prognostic potential of inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) in viral hepatitis patients.</div></div><div><h3>Methods</h3><div>We conducted a systematic search in online databases of PubMed, Web of Science, Scopus, and Cochrane for related articles following PRISMA guidelines. Our endpoint was to evaluate the association between NLR, PLR, MPV, PDW, and RDW with fibrosis and cirrhosis outcomes in patients with hepatitis B and C. The analysis used the \"meta\" package in R, employing Hedges' g to calculate the standardized mean difference (SMD) and 95 % confidence intervals (CI). A P value less than 0.05 was considered statistically significant for all data analyses</div></div><div><h3>Results</h3><div>Thirty-seven studies were ultimately included in the analysis. PLR was higher in mild fibrosis (SMD = -0.48, 95 % CI: -0.90; -0.06), with no significant differences observed by hepatitis type. Both MPV and RDW were higher in advanced fibrosis (MPV: SMD = 0.36, 95 % CI: 0.19; 0.53, RDW: SMD = 0.32, 95 % CI: 0.14; 0.50), and they were significantly increased in advanced hepatitis C fibrosis. PDW was higher in advanced fibrosis (SMD = 0.32, 95 % CI: 0.02; 0.61), significantly in hepatitis B. In cirrhotic versus non-cirrhotic patients, MPV (SMD = 0.22, 95 % CI: 0.07; 0.38) and RDW (SMD = 1.35, 95 % CI: 0.62; 2.08) were higher in the cirrhotic group, while PLR (SMD = -1.15, 95 % CI: -2.16; -0.15) was higher in the non-cirrhotic group. NLR showed no significant difference between mild and advanced fibrosis or between cirrhotic and non-cirrhotic groups.</div></div><div><h3>Conclusion</h3><div>This meta-analysis reveals the importance of hematological parameters of MPV, PDW, RDW, and PLR as predictors of viral hepatitis progression. MPV, PDW, and RDW are elevated in advanced fibrosis, while PLR is notably higher in mild fibrosis.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100229"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance of dried blood spot sampling in quantifying hepatitis B DNA in Vietnam 干血点取样在越南乙型肝炎DNA定量分析中的应用

IF 1.4 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-11-01 Epub Date: 2025-10-06 DOI: 10.1016/j.jcvp.2025.100230

Manh-Tuan Ha , Duyen Thi-My Nguyen , Tuan-Anh Nguyen

Background

Sampling is a crucial step in quantifying HBV DNA. In some situations, dried blood spot (DBS) sampling is required. This study aimed to validate the accuracy of HBV DNA quantification from DBS samples and to evaluate the stability of HBV DNA levels under practical storage conditions.

Materials and Methods

We collected paired serum and DBS samples from HBV DNA-positive cases and HBV DNA-negative controls (1:1 ratio). The validity of DBS samples in HBV DNA quantification was determined using serum results as a gold standard.

Results

The study analyzed 100 paired DBS and serum samples from both cases and controls. It reported relatively high sensitivity (86.7%) and specificity (97.6%) for DBS samples in detecting HBV DNA levels greater than 2000 IU/mL. A strong linear regression correlation was found between HBV DNA levels in DBS and serum samples, with an R² of 0.8679 (p < 0.001) and the regression equation y = 0.9095x - 0.7792. The mean difference in HBV DNA levels between DBS and serum was 1.28 ± 0.78 log10 IU/mL. Notably, differences in HBV DNA levels in DBS samples remained insignificant after 14 days of storage at both 4°C and room temperature (p>0.05), indicating stability under various storage conditions.

Conclusion

This study demonstrates that DBS samples are effective for identifying patients eligible for treatment and remain stable at room temperature for at least 14 days, supporting their feasibility in real-world settings. The use of DBS samples for monitoring hepatitis B treatment response and optimizing the elution process presents promising research opportunities.

背景：采样是定量HBV DNA的关键步骤。在某些情况下，需要进行干血斑（DBS）取样。本研究旨在验证DBS样品中HBV DNA定量的准确性，并评估HBV DNA水平在实际储存条件下的稳定性。材料与方法以1:1的比例采集HBV dna阳性和HBV dna阴性对照的血清和DBS样本。以血清结果作为金标准，确定DBS样品在HBV DNA定量中的有效性。结果本研究分析了来自病例和对照组的100对DBS和血清样本。据报道，DBS样本检测HBV DNA水平高于2000 IU/mL的灵敏度（86.7%）和特异性（97.6%）相对较高。DBS中HBV DNA水平与血清样本呈强线性回归相关，R²为0.8679 (p < 0.001)，回归方程为y = 0.9095x - 0.7792。DBS与血清中HBV DNA水平的平均差异为1.28±0.78 log10 IU/mL。值得注意的是，在4°C和室温下保存14天后，DBS样品中HBV DNA水平的差异仍然不显著（p>0.05），表明在各种保存条件下都是稳定的。结论DBS样品可有效识别适合治疗的患者，并在室温下保持至少14天的稳定性，支持其在现实环境中的可行性。DBS样本用于监测乙型肝炎治疗反应和优化洗脱过程提供了有前途的研究机会。

{"title":"Performance of dried blood spot sampling in quantifying hepatitis B DNA in Vietnam","authors":"Manh-Tuan Ha , Duyen Thi-My Nguyen , Tuan-Anh Nguyen","doi":"10.1016/j.jcvp.2025.100230","DOIUrl":"10.1016/j.jcvp.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>Sampling is a crucial step in quantifying HBV DNA. In some situations, dried blood spot (DBS) sampling is required. This study aimed to validate the accuracy of HBV DNA quantification from DBS samples and to evaluate the stability of HBV DNA levels under practical storage conditions.</div></div><div><h3>Materials and Methods</h3><div>We collected paired serum and DBS samples from HBV DNA-positive cases and HBV DNA-negative controls (1:1 ratio). The validity of DBS samples in HBV DNA quantification was determined using serum results as a gold standard.</div></div><div><h3>Results</h3><div>The study analyzed 100 paired DBS and serum samples from both cases and controls. It reported relatively high sensitivity (86.7%) and specificity (97.6%) for DBS samples in detecting HBV DNA levels greater than 2000 IU/mL. A strong linear regression correlation was found between HBV DNA levels in DBS and serum samples, with an R² of 0.8679 (p < 0.001) and the regression equation y = 0.9095x - 0.7792. The mean difference in HBV DNA levels between DBS and serum was 1.28 ± 0.78 log10 IU/mL. Notably, differences in HBV DNA levels in DBS samples remained insignificant after 14 days of storage at both 4°C and room temperature (p>0.05), indicating stability under various storage conditions.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that DBS samples are effective for identifying patients eligible for treatment and remain stable at room temperature for at least 14 days, supporting their feasibility in real-world settings. The use of DBS samples for monitoring hepatitis B treatment response and optimizing the elution process presents promising research opportunities.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100230"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145266558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic reactogenicity is a correlate of MF59 adjuvant-moderated immunogenicity in influenza vaccinated children 流感疫苗接种儿童的全身反应原性与MF59佐剂调节的免疫原性相关

IF 1.4 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-11-01 Epub Date: 2025-10-30 DOI: 10.1016/j.jcvp.2025.100234

Charlotte Switzer , Chris P. Verschoor , Eleanor Pullenayegum , Pardeep Singh , Mark Loeb

Background

Adjuvanted influenza vaccine induces more robust antibody responses, but is associated with more adverse events following vaccination. Prior work has examined the link between vaccine reactions and immunogenicity in adults, but little is known about the association between reactogenicity and postvaccination antibody responses in children, particularly regarding adjuvanted influenza vaccine. This study examines the relationship between reactogenicity and immunogenicity in children vaccinated against influenza, and the immunomodulatory effects of the adjuvant.

Methods

We conducted a secondary analysis of data from a cluster-randomized trial of children aged 6 to 72 months from Canadian Hutterite colonies. Participants received either a trivalent MF59-adjuvanted vaccine (aTIV) or a quadrivalent non-adjuvanted vaccine (QIV). Reactogenicity was measured using a composite score based on local, systemic, and respiratory reactions recorded within five days post-vaccination. Immunogenicity was assessed by measuring hemagglutination inhibition (HAI) titers before and four weeks after vaccination. Linear mixed models were used to evaluate associations between reactogenicity scores and post-vaccination log-transformed HAI titers.

Results

In adjuvanted vaccinees, higher systemic reactogenicity scores were associated with increased antibody titers for A/H1N1 and B/Victoria, relative to nonadjuvanted vaccinees (β: 0.38, 95 % CI: 0.17 to 0.60; and (β: 0.44, 95 % CI: 0.24 to 0.64 respectively). Higher systemic reactogenicity in nonadjuvanted vaccinees correlated with reduced post-vaccination antibody titers for A/H1N1 (β:0.36, 95 % CI:0.54 to -0.18) and B/Victoria (β:0.37, 95 % CI:0.54 to -0.20). Respiratory reactogenicity was positively correlated with immunogenicity in responses to A/H3N2 in the adjuvanted group (β: 0.78, 95 % CI: 0.13 to 1.43). Local reactogenicity was associated with A/H1N1 immunogenicity, but showed no significant interaction with vaccine formulation (β: 0.25, 95 % CI: 0.04 to 0.47).

Conclusions

Systemic reactogenicity in adjuvanted vaccinees showed positive correlations with immunogenicity, whereas reactogenicity contributed to blunting of antibody responses in nonadjuvanted vaccinees. We found that stronger systemic reactions correlate with improved immune responses in the adjuvanted group against all vaccine strains save A/H3N2, which warrants further investigation. Our study finds that reactogenicity is a modest biomarker for vaccine immunogenicity, and that the increased reactogenicity of the adjuvanted vaccine is associated with enhanced immune responsiveness, which may predict greater vaccine effectiveness.

背景：佐剂流感疫苗可诱导更强的抗体应答，但在接种后与更多不良事件相关。先前的工作已经研究了成人疫苗反应与免疫原性之间的联系，但对儿童疫苗反应原性与疫苗接种后抗体反应之间的关系知之甚少，特别是关于佐剂流感疫苗。本研究探讨儿童接种流感疫苗的反应原性和免疫原性之间的关系，以及佐剂的免疫调节作用。方法我们对来自加拿大huterite殖民地的6至72个月儿童的集群随机试验数据进行了二次分析。参与者接受三价mf59佐剂疫苗（aTIV）或四价非佐剂疫苗（QIV）。使用基于接种后5天内记录的局部、全身和呼吸反应的综合评分来测量反应原性。免疫原性通过测定疫苗接种前和接种后四周的血凝抑制（HAI）滴度来评估。使用线性混合模型来评估反应性评分与接种后对数转换的HAI滴度之间的关系。结果在接种佐剂疫苗的人群中，与未接种佐剂疫苗的人群相比，更高的系统反应原性评分与更高的A/H1N1和B/Victoria抗体滴度相关（β: 0.38, 95% CI: 0.17 ~ 0.60; β: 0.44, 95% CI: 0.24 ~ 0.64）。非佐剂疫苗接种者较高的全身反应原性与疫苗接种后A/H1N1抗体滴度（β:0.36, 95% CI:0.54至-0.18）和B/Victoria抗体滴度（β:0.37, 95% CI:0.54至-0.20）降低相关。A/H3N2佐剂组呼吸反应原性与免疫原性呈正相关（β: 0.78, 95% CI: 0.13 ~ 1.43）。局部反应原性与A/H1N1免疫原性相关，但与疫苗制剂无显著相互作用（β: 0.25, 95% CI: 0.04 ~ 0.47）。结论佐剂疫苗接种者的全身反应原性与免疫原性呈正相关，而非佐剂疫苗接种者的全身反应原性与抗体反应钝化有关。我们发现，在佐剂组中，更强的全身反应与对除A/H3N2以外的所有疫苗株的免疫反应改善相关，这值得进一步研究。我们的研究发现，反应原性是疫苗免疫原性的适度生物标志物，佐剂疫苗反应原性的增加与免疫反应性的增强有关，这可能预示着更大的疫苗有效性。

{"title":"Systemic reactogenicity is a correlate of MF59 adjuvant-moderated immunogenicity in influenza vaccinated children","authors":"Charlotte Switzer , Chris P. Verschoor , Eleanor Pullenayegum , Pardeep Singh , Mark Loeb","doi":"10.1016/j.jcvp.2025.100234","DOIUrl":"10.1016/j.jcvp.2025.100234","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvanted influenza vaccine induces more robust antibody responses, but is associated with more adverse events following vaccination. Prior work has examined the link between vaccine reactions and immunogenicity in adults, but little is known about the association between reactogenicity and postvaccination antibody responses in children, particularly regarding adjuvanted influenza vaccine. This study examines the relationship between reactogenicity and immunogenicity in children vaccinated against influenza, and the immunomodulatory effects of the adjuvant.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis of data from a cluster-randomized trial of children aged 6 to 72 months from Canadian Hutterite colonies. Participants received either a trivalent MF59-adjuvanted vaccine (aTIV) or a quadrivalent non-adjuvanted vaccine (QIV). Reactogenicity was measured using a composite score based on local, systemic, and respiratory reactions recorded within five days post-vaccination. Immunogenicity was assessed by measuring hemagglutination inhibition (HAI) titers before and four weeks after vaccination. Linear mixed models were used to evaluate associations between reactogenicity scores and post-vaccination log-transformed HAI titers.</div></div><div><h3>Results</h3><div>In adjuvanted vaccinees, higher systemic reactogenicity scores were associated with increased antibody titers for A/H1N1 and B/Victoria, relative to nonadjuvanted vaccinees (β: 0.38, 95 % CI: 0.17 to 0.60; and (β: 0.44, 95 % CI: 0.24 to 0.64 respectively). Higher systemic reactogenicity in nonadjuvanted vaccinees correlated with reduced post-vaccination antibody titers for A/H1N1 (β:0.36, 95 % CI:0.54 to -0.18) and B/Victoria (β:0.37, 95 % CI:0.54 to -0.20). Respiratory reactogenicity was positively correlated with immunogenicity in responses to A/H3N2 in the adjuvanted group (β: 0.78, 95 % CI: 0.13 to 1.43). Local reactogenicity was associated with A/H1N1 immunogenicity, but showed no significant interaction with vaccine formulation (β: 0.25, 95 % CI: 0.04 to 0.47).</div></div><div><h3>Conclusions</h3><div>Systemic reactogenicity in adjuvanted vaccinees showed positive correlations with immunogenicity, whereas reactogenicity contributed to blunting of antibody responses in nonadjuvanted vaccinees. We found that stronger systemic reactions correlate with improved immune responses in the adjuvanted group against all vaccine strains save A/H3N2, which warrants further investigation. Our study finds that reactogenicity is a modest biomarker for vaccine immunogenicity, and that the increased reactogenicity of the adjuvanted vaccine is associated with enhanced immune responsiveness, which may predict greater vaccine effectiveness.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100234"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

China reports first human case of Mpox: A call for global surveillance for public health and policy 中国报告首例人痘病例：呼吁全球公共卫生和政策监测

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-08-01 Epub Date: 2025-07-16 DOI: 10.1016/j.jcvp.2025.100226

Uthman Okikiola Adebayo , Tolutope Adebimpe Oso , Safayet Jamil , Olalekan John Okesanya , Mohamed Mustaf Ahmed

引用次数: 0

Frequency and clinical characteristics of human bocavirus in respiratory illnesses across diverse age groups in Lagos, Nigeria 尼日利亚拉各斯不同年龄组呼吸道疾病中人类博卡病毒的频率和临床特征

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-08-01 Epub Date: 2025-06-28 DOI: 10.1016/j.jcvp.2025.100225

Abdul-Azeez A. Anjorin , Oluwaseyi S. Ashaka , Joseph Eyedo , Abdulrauf O. Abdulkareem , Taofeeq A. Balogun , Zainab B. Salami , Kabiru O. Akinyemi

Background

Human Bocavirus (HBoV) first described by Allander and colleagues in 2005 is one of the most common viral pathogens causing respiratory diseases. It is a single-stranded DNA virus from the Parvoviridae family that is associated with respiratory and gastrointestinal infections. The prevalence and impact of the HBoV in Lagos, Nigeria, particularly across all age groups, remain underexplored.

Aim

This study aimed to determine the prevalence of HBoV among individuals with respiratory symptoms and its association with disease in Lagos, Nigeria.

Methods

A hospital-based, cross-sectional study was conducted from December 2022 to May 2023 in Lagos. Nasopharyngeal swabs were collected from 400 participants presenting with respiratory symptoms across diverse age groups. The samples were analysed for HBoV DNA using real-time PCR. Demographic and clinical data were recorded, and statistical analysis was performed using SPSS.

Results

The overall prevalence of HBoV was 12.5 % (57/400), with a higher 24.6 % prevalence in participants aged 21–30 years than 8.4 % in those aged ≤10 years. The participants diagnosed with respiratory disease had a significantly greater 20.3 % prevalence of HBoV compared to 8.4 % without respiratory disease (χ²=11.69, p = 0.0006). Fever and runny nose were the most common symptoms among HBoV-positive participants, regardless of respiratory disease status.

Conclusions

HBoV is prevalent in Lagos and contributes significantly to respiratory illnesses across all age groups, with the highest burden observed in young adults. These findings underscore the need for further research on the clinical implications of HBoV and its potential for nosocomial transmission in healthcare settings.

人类bocavavirus （HBoV）于2005年由Allander及其同事首次描述，是引起呼吸道疾病的最常见的病毒性病原体之一。它是细小病毒科的一种单链DNA病毒，与呼吸道和胃肠道感染有关。在尼日利亚拉各斯，特别是在所有年龄组中，HBoV的流行和影响仍未得到充分探讨。目的本研究旨在确定尼日利亚拉各斯有呼吸道症状个体中HBoV的流行情况及其与疾病的关系。方法于2022年12月至2023年5月在拉各斯进行了一项以医院为基础的横断面研究。收集了来自不同年龄组的400名有呼吸道症状的参与者的鼻咽拭子。采用实时PCR对样品进行HBoV DNA分析。记录人口学及临床资料，采用SPSS软件进行统计学分析。结果HBoV的总患病率为12.5%(57/400)，其中21-30岁人群的患病率为24.6%，高于≤10岁人群的8.4%。诊断为呼吸系统疾病的参与者的HBoV患病率为20.3%，而未诊断为呼吸系统疾病的参与者的HBoV患病率为8.4% （χ²=11.69,p = 0.0006）。无论呼吸道疾病状况如何，hbov阳性参与者中最常见的症状是发烧和流鼻涕。结论shbov在拉各斯流行，对所有年龄组的呼吸系统疾病都有显著影响，其中年轻人的负担最高。这些发现强调需要进一步研究HBoV的临床意义及其在卫生保健机构中医院传播的可能性。

{"title":"Frequency and clinical characteristics of human bocavirus in respiratory illnesses across diverse age groups in Lagos, Nigeria","authors":"Abdul-Azeez A. Anjorin , Oluwaseyi S. Ashaka , Joseph Eyedo , Abdulrauf O. Abdulkareem , Taofeeq A. Balogun , Zainab B. Salami , Kabiru O. Akinyemi","doi":"10.1016/j.jcvp.2025.100225","DOIUrl":"10.1016/j.jcvp.2025.100225","url":null,"abstract":"<div><h3>Background</h3><div>Human Bocavirus (HBoV) first described by Allander and colleagues in 2005 is one of the most common viral pathogens causing respiratory diseases. It is a single-stranded DNA virus from the Parvoviridae family that is associated with respiratory and gastrointestinal infections. The prevalence and impact of the HBoV in Lagos, Nigeria, particularly across all age groups, remain underexplored.</div></div><div><h3>Aim</h3><div>This study aimed to determine the prevalence of HBoV among individuals with respiratory symptoms and its association with disease in Lagos, Nigeria.</div></div><div><h3>Methods</h3><div>A hospital-based, cross-sectional study was conducted from December 2022 to May 2023 in Lagos. Nasopharyngeal swabs were collected from 400 participants presenting with respiratory symptoms across diverse age groups. The samples were analysed for HBoV DNA using real-time PCR. Demographic and clinical data were recorded, and statistical analysis was performed using SPSS.</div></div><div><h3>Results</h3><div>The overall prevalence of HBoV was 12.5 % (57/400), with a higher 24.6 % prevalence in participants aged 21–30 years than 8.4 % in those aged ≤10 years. The participants diagnosed with respiratory disease had a significantly greater 20.3 % prevalence of HBoV compared to 8.4 % without respiratory disease (χ²=11.69, <em>p</em> = 0.0006). Fever and runny nose were the most common symptoms among HBoV-positive participants, regardless of respiratory disease status.</div></div><div><h3>Conclusions</h3><div>HBoV is prevalent in Lagos and contributes significantly to respiratory illnesses across all age groups, with the highest burden observed in young adults. These findings underscore the need for further research on the clinical implications of HBoV and its potential for nosocomial transmission in healthcare settings.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100225"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144550047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance of an automated platform for CMV, EBV and BKPyV DNA detection and quantification CMV， EBV和BKPyV DNA检测和定量自动化平台的性能

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-08-01 Epub Date: 2025-07-16 DOI: 10.1016/j.jcvp.2025.100228

Yoann Fluhr , Karine Saune , Kevin Oliveira-Mendes , Estelle Raguin , Lila Poiteau , Arnaud Del Bello , Nassim Kamar , Jacques Izopet , Florence Abravanel

Quantification of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK polyomavirus (BKPyV) DNA is crucial for diagnosing related infections. The analytical performance of the Altostar® CMV, EBV and BKPyV DNA assays used in the AltoStar® AM16 instrument was assessed.

The Limit of detection was 215 international units/ml (IU/ml) for the CMV assay, 330 IU/ml for the EBV assay and 133 IU/ml for the BKPyV assay. A good concordance was found between the nominal value of the NIBSC standards and the AltoStar® results. Linearity was verified up to 5.7 log₁₀ IU/ml. Intra-assay and inter-assay reproducibility showed low disparity with a standard deviation < 0.27 log₁₀ IU/ml.

The concordance with our previous DNA assays on clinical samples for CMV detection was 95.5% (n = 22), 90.6% for EBV (n = 32) and 92% for BKV (n = 25). The quantitative results were highly correlated.

The Altostar® platform provides accurate quantification for clinical monitoring of CMV, EBV and BKPyV DNA.

巨细胞病毒（CMV）、eb病毒（EBV）和BK多瘤病毒（BKPyV） DNA的定量检测对相关感染的诊断至关重要。评估Altostar®AM16仪器中使用的Altostar®CMV、EBV和BKPyV DNA检测的分析性能。CMV检测限为215国际单位/ml (IU/ml)， EBV检测限为330 IU/ml， BKPyV检测限为133 IU/ml。在NIBSC标准的标称值与AltoStar®结果之间发现了良好的一致性。在5.7 log10 IU/ml的线性范围内验证。测定内和测定间重现性差异低，标准差为<；0.27 log10 IU/ml。临床样本CMV检测与既往DNA检测的一致性为95.5% (n = 22)， EBV检测为90.6% (n = 32)， BKV检测为92% （n = 25）。定量结果高度相关。Altostar®平台为CMV、EBV和BKPyV DNA的临床监测提供准确的定量。

{"title":"Performance of an automated platform for CMV, EBV and BKPyV DNA detection and quantification","authors":"Yoann Fluhr , Karine Saune , Kevin Oliveira-Mendes , Estelle Raguin , Lila Poiteau , Arnaud Del Bello , Nassim Kamar , Jacques Izopet , Florence Abravanel","doi":"10.1016/j.jcvp.2025.100228","DOIUrl":"10.1016/j.jcvp.2025.100228","url":null,"abstract":"<div><div>Quantification of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK polyomavirus (BKPyV) DNA is crucial for diagnosing related infections. The analytical performance of the Altostar® CMV, EBV and BKPyV DNA assays used in the AltoStar® AM16 instrument was assessed.</div><div>The Limit of detection was 215 international units/ml (IU/ml) for the CMV assay, 330 IU/ml for the EBV assay and 133 IU/ml for the BKPyV assay. A good concordance was found between the nominal value of the NIBSC standards and the AltoStar® results. Linearity was verified up to 5.7 log<sub>10</sub> IU/ml. Intra-assay and inter-assay reproducibility showed low disparity with a standard deviation < 0.27 log<sub>10</sub> IU/ml.</div><div>The concordance with our previous DNA assays on clinical samples for CMV detection was 95.5% (<em>n</em> = 22), 90.6% for EBV (<em>n</em> = 32) and 92% for BKV (<em>n</em> = 25). The quantitative results were highly correlated.</div><div>The Altostar® platform provides accurate quantification for clinical monitoring of CMV, EBV and BKPyV DNA.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100228"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Divergent origins, divergent pandemic potential: A comparative analysis of HMPV and SARS-CoV-2 不同的起源，不同的大流行潜力：HMPV和SARS-CoV-2的比较分析

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-08-01 Epub Date: 2025-06-12 DOI: 10.1016/j.jcvp.2025.100223

Fateme Mozaffari , Setayesh Fakhari , Ameneh Elikaei , Zahra Ahmadi , Behrokh Farahmand , Ali Maleki

The study of Human Metapneumovirus (HMPV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have critical importance due to their significant impact on the respiratory system and public health worldwide. Although they have different transmission dynamics, disease severity, and immune responses, both viruses are major causes of respiratory disorders. Focusing on their structural features, clinical symptoms, and epidemiological trends, this paper seeks to find the parallels and contrasts between HMPV and SARS-CoV-2. Although both viruses are RNA-based and cause acute respiratory illnesses, SARS-CoV-2 has caused a worldwide pandemic with high rates of transmission and severe consequences including great morbidity and mortality. While HMPV mostly causes minor respiratory problems, it still places a significant burden on vulnerable groups, especially children, the elderly, and immunocompromised people. Important variations noted include HMPV shows more confined seasonal outbreaks while SARS-CoV-2′s increased transmission rate and rapid evolution lead to the emergence of new variants.

Several factors currently limit HMPV's potential to cause pandemics. Its relatively low basic reproduction number (R0), lack of a non-human host that reduces opportunities for it to jump from animal reservoirs, non-segmented genome that prevents reassortment, and its low evolutionary rate. Moreover, HMPV is not an emerging virus, and has been circulating in humans for several decades. Therefore, a basic level of immunity already exists.

人偏肺病毒（HMPV）和严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）的研究对全球呼吸系统和公共卫生产生重大影响，因此具有至关重要的意义。尽管它们具有不同的传播动态、疾病严重程度和免疫反应，但这两种病毒都是导致呼吸系统疾病的主要原因。本文从HMPV和SARS-CoV-2的结构特征、临床症状和流行病学趋势等方面进行对比分析。尽管这两种病毒都是以rna为基础并引起急性呼吸道疾病，但SARS-CoV-2已引起全球大流行，传播率高，后果严重，包括发病率和死亡率高。虽然人乳头状瘤病毒主要引起轻微的呼吸问题，但它仍然给弱势群体，特别是儿童、老年人和免疫功能低下的人造成重大负担。注意到的重要变异包括HMPV表现出更有限的季节性暴发，而SARS-CoV-2的传播率增加和快速进化导致新变种的出现。目前有几个因素限制了HMPV引起大流行的可能性。它的基本繁殖数（R0）相对较低，缺乏非人类宿主，减少了从动物宿主跳跃的机会，非片段基因组防止了重组，并且其进化速度较低。此外，HMPV不是一种新出现的病毒，已经在人类中传播了几十年。因此，已经存在基本的免疫水平。

{"title":"Divergent origins, divergent pandemic potential: A comparative analysis of HMPV and SARS-CoV-2","authors":"Fateme Mozaffari , Setayesh Fakhari , Ameneh Elikaei , Zahra Ahmadi , Behrokh Farahmand , Ali Maleki","doi":"10.1016/j.jcvp.2025.100223","DOIUrl":"10.1016/j.jcvp.2025.100223","url":null,"abstract":"<div><div>The study of Human Metapneumovirus (HMPV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have critical importance due to their significant impact on the respiratory system and public health worldwide. Although they have different transmission dynamics, disease severity, and immune responses, both viruses are major causes of respiratory disorders. Focusing on their structural features, clinical symptoms, and epidemiological trends, this paper seeks to find the parallels and contrasts between HMPV and SARS-CoV-2. Although both viruses are RNA-based and cause acute respiratory illnesses, SARS-CoV-2 has caused a worldwide pandemic with high rates of transmission and severe consequences including great morbidity and mortality. While HMPV mostly causes minor respiratory problems, it still places a significant burden on vulnerable groups, especially children, the elderly, and immunocompromised people. Important variations noted include HMPV shows more confined seasonal outbreaks while SARS-CoV-2′s increased transmission rate and rapid evolution lead to the emergence of new variants.</div><div>Several factors currently limit HMPV's potential to cause pandemics. Its relatively low basic reproduction number (R0), lack of a non-human host that reduces opportunities for it to jump from animal reservoirs, non-segmented genome that prevents reassortment, and its low evolutionary rate. Moreover, HMPV is not an emerging virus, and has been circulating in humans for several decades. Therefore, a basic level of immunity already exists.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100223"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0